SG11201601230RA - Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses - Google Patents

Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

Info

Publication number
SG11201601230RA
SG11201601230RA SG11201601230RA SG11201601230RA SG11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA SG 11201601230R A SG11201601230R A SG 11201601230RA
Authority
SG
Singapore
Prior art keywords
synthesis
methods
pharmaceutical compositions
therapeutic uses
macrolide
Prior art date
Application number
SG11201601230RA
Inventor
Thomas Nittoli
Nareshkumar F Jain
Thomas Patrick Markotan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201601230RA publication Critical patent/SG11201601230RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
SG11201601230RA 2013-08-26 2014-08-26 Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses SG11201601230RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869954P 2013-08-26 2013-08-26
US201461934313P 2014-01-31 2014-01-31
PCT/US2014/052757 WO2015031396A1 (en) 2013-08-26 2014-08-26 Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

Publications (1)

Publication Number Publication Date
SG11201601230RA true SG11201601230RA (en) 2016-03-30

Family

ID=51542449

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601230RA SG11201601230RA (en) 2013-08-26 2014-08-26 Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

Country Status (17)

Country Link
US (3) US20160354482A1 (en)
EP (1) EP3038624A1 (en)
JP (1) JP6608823B2 (en)
KR (1) KR102252925B1 (en)
CN (1) CN105530942B (en)
AU (1) AU2014311361B2 (en)
BR (1) BR112016004023A2 (en)
CA (1) CA2921412A1 (en)
CL (1) CL2016000408A1 (en)
EA (1) EA038192B1 (en)
HK (1) HK1220115A1 (en)
IL (1) IL244203B (en)
MX (1) MX2016002149A (en)
PH (1) PH12016500380A1 (en)
SG (1) SG11201601230RA (en)
WO (1) WO2015031396A1 (en)
ZA (1) ZA201601534B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964237A1 (en) 2013-03-15 2022-03-09 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
MX2016002149A (en) 2013-08-26 2016-10-28 Regeneron Pharma Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses.
SG11201707148PA (en) * 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
EP3722318A1 (en) 2015-07-06 2020-10-14 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
CN114478801A (en) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 Maytansinoid derivatives, conjugates thereof, and methods of use
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EA201990781A9 (en) 2016-09-23 2019-11-27 ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION
DK3515487T3 (en) 2016-09-23 2023-08-28 Regeneron Pharma Bispecific anti-MUC16-CD3 antibodies and anti-MUC16 drug conjugates
TWI782930B (en) * 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
MX2019013690A (en) 2017-05-18 2020-01-27 Regeneron Pharma Cyclodextrin protein drug conjugates.
WO2019212965A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
EA202091135A1 (en) 2018-05-09 2020-10-14 Регенерон Фармасьютикалз, Инк. HYDROPHILIC LINKERS FOR ANTI-BODY-DRUG CONJUGATE CONJUGATES
MX2020012350A (en) 2018-05-17 2021-01-29 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof.
EP3927435A1 (en) 2019-02-21 2021-12-29 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
MX2022002886A (en) 2019-09-16 2022-04-06 Regeneron Pharma Radiolabeled met binding proteins for immuno-pet imaging.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
EP4110472A1 (en) 2020-02-28 2023-01-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
KR20240038138A (en) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
CN116406379A (en) 2020-10-22 2023-07-07 瑞泽恩制药公司 anti-FGFR 2 antibodies and methods of use thereof
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
CN115215780B (en) * 2022-04-22 2023-08-08 上海格苓凯生物科技有限公司 Method for preparing heterobifunctional crosslinking agent SMCC by using N, N-disuccinimidyl carbonate

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004260936B2 (en) 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AR048098A1 (en) 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
BRPI0515745A (en) 2004-12-09 2008-08-05 Centocor Inc antiintegrin immunoconjugates, methods and uses
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
PT2502938E (en) 2006-10-27 2015-06-05 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
CA2687178C (en) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
ES2629405T3 (en) * 2008-03-18 2017-08-09 Genentech, Inc. Combinations of a drug-antibody anti-HER2 and docetaxel conjugate
WO2009134976A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
EP2464972A1 (en) 2009-08-10 2012-06-20 UCL Business PLC Reversible covalent linkage of functional molecules
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
KR20120080611A (en) * 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 Potent conjugates and hydrophilic linkers
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
TWI540136B (en) 2010-04-15 2016-07-01 梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
JP6146913B2 (en) 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Mice producing a binding protein containing a VL domain
PT2611785E (en) 2010-09-01 2014-09-09 Bayer Ip Gmbh N-(tetrazol-5-yl)- and n-(triazol-5-yl)aryl carboxylic acid amides and use of same as herbicides
CN105399831A (en) 2010-10-29 2016-03-16 伊缪诺金公司 Non-antagonistic egfr-binding molecules and immunoconjugates thereof
AU2011323316B2 (en) 2010-11-03 2016-02-25 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012156919A1 (en) 2011-05-16 2012-11-22 Koninklijke Philips Electronics N.V. Bio-orthogonal drug activation
ES2898854T3 (en) 2011-05-27 2022-03-09 Ambrx Inc Compositions Containing, Methods Involving, and Uses of Unnatural Amino Acid Linked Dolastatin Derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9289512B2 (en) 2011-06-21 2016-03-22 Immunogen, Inc. Maytansinoid derivatives with peptide linker and conjugates thereof
JP6399930B2 (en) 2011-10-14 2018-10-03 シアトル ジェネティクス，インコーポレーテッド Pyrrolobenzodiazepine and target conjugates
JP6393617B2 (en) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド Pyrrolobenzodiazepine and target conjugates
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
WO2013053872A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
MX2014015682A (en) 2012-06-19 2015-07-23 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates.
CN110201186A (en) 2012-10-23 2019-09-06 西纳福克斯股份有限公司 Modified antibody, antibody-conjugate and preparation method thereof
NO2789793T3 (en) 2012-10-24 2018-01-27
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (en) * 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
CN104688740A (en) 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 Related maytansine derivatives and preparation method and application thereof
CN103254213B (en) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 Preparation method of maytenin-like ester and composition used in method
EP3964237A1 (en) 2013-03-15 2022-03-09 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CN103254311B (en) * 2013-05-09 2015-05-13 齐鲁制药有限公司 Method for preparing antibody-maytansine alkaloid medicine conjugate
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
ES2891755T3 (en) 2013-06-06 2022-01-31 Pf Medicament Anti-C10orf54 antibodies and uses thereof
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
MX2016002149A (en) 2013-08-26 2016-10-28 Regeneron Pharma Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses.
JP6745218B2 (en) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド Methods for producing hydrazinyl-pyrrolo compounds and conjugates
WO2015081857A1 (en) 2013-12-02 2015-06-11 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
EP3148592A2 (en) 2014-06-02 2017-04-05 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
CN114478801A (en) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 Maytansinoid derivatives, conjugates thereof, and methods of use

Also Published As

Publication number Publication date
AU2014311361B2 (en) 2018-11-29
JP2016528304A (en) 2016-09-15
EA201600191A1 (en) 2016-07-29
NZ716768A (en) 2021-10-29
CN105530942B (en) 2019-10-11
HK1220115A1 (en) 2017-04-28
KR102252925B1 (en) 2021-05-18
JP6608823B2 (en) 2019-11-20
IL244203B (en) 2018-12-31
ZA201601534B (en) 2023-11-29
CL2016000408A1 (en) 2017-02-24
NZ756518A (en) 2021-10-29
KR20160045146A (en) 2016-04-26
WO2015031396A1 (en) 2015-03-05
EP3038624A1 (en) 2016-07-06
IL244203A0 (en) 2016-04-21
MX2016002149A (en) 2016-10-28
US11596635B2 (en) 2023-03-07
AU2014311361A1 (en) 2016-03-03
PH12016500380A1 (en) 2016-05-16
EA201600191A8 (en) 2018-04-30
US20230321109A1 (en) 2023-10-12
CN105530942A (en) 2016-04-27
CA2921412A1 (en) 2015-03-05
US20190151323A1 (en) 2019-05-23
BR112016004023A2 (en) 2022-11-16
US20160354482A1 (en) 2016-12-08
EA038192B1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
HK1220115A1 (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical compositions containing them
EP2981611A4 (en) Antibiotic protocells and related pharmaceutical formulations and methods of treatment
HK1220980A1 (en) Methods and compositions for treatment of pompe disease
IL240876B (en) Aminopurine derivatives, their preparation and pharmaceutical compositions containing them
IL240290B (en) Pyridazinone-amides derivatives and pharmaceutical compositions containing them
IL243608A0 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
SG11201507347QA (en) Pharmaceutical composition of s-ketamine hydrochloride
SG10201912735TA (en) Pharmaceutical composition of s-ketamine hydrochloride
HK1220920A1 (en) Therapeutic compositions and uses thereof
IL242347B (en) Macrocyclic compounds, their preparation and pharmaceutical compositions containing them
SG11201601047SA (en) Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
ZA201802033B (en) Heteroaryl compounds and their use as therapeutic drugs
IL243733A0 (en) Cyclopentane derivatives, their preparation and medicaments containing them
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
IL246406A0 (en) Imidazopyrazinone derivatives, their preparation and pharmaceutical compositions containing them
IL239054A0 (en) Azaquinazoline carboxamide derivatives, their preparation and pharmaceutical compositions containing them
IL246298B (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
IL243227B (en) Diaminocyclopentane carboxamide derivatives, their preparation and pharmaceutical compositions containing them
IL239873A0 (en) Piperidinylcarbazole derivatives, their preparation and pharmaceutical compositions containing them
HK1209127A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof